Amoneta  Diagnostics is a life sciences biotechnology company that identifies, develops and qualifies innovative biomarkers for the development of diagnostics and diagnostic tools in the field of neurological diseases. The Amoneta Diagnostics team, which is coordinating the ADDIA consortium has a vast expertise in the discovery and development of biomarkers for driving the development of biomarker-based diagnostic kits, enabling the improvement of disease outcome, increase of patient comfort, better therapeutic decisions and significant savings in healthcare.

The ultimate mission of the company is to translate new diagnostic methods for various neurodegenerative diseases into products (tests) and to promote the use of these tests in clinical practice.

For more information on Amoneta Diagnostics S.A.S. and the team, please visit www.amoneta-diagnostics.com

ADDIA is funded by HORIZON 2020
Research & Innovation Programme
< E.C. Grant Agreement # 674474 >